{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:07:55Z","timestamp":1784196475609,"version":"3.55.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is one of the most common cancers affecting men worldwide and its prevalence is rising in India. The disease primarily affects older men, with incidence increasing with age, and a substantial proportion present with advanced or metastatic disease at diagnosis. Simultaneously, cardiovascular disease (CVD) remains highly prevalent in the Indian population, representing a major cause of non-cancer mortality. The intersection of PCa, its treatment, and cardiovascular comorbidities presents a complex clinical challenge, particularly as therapies such as androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) improve overall survival but carry cardiometabolic risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Prostate Cancer Cardiovascular (PCCV) Risk Expert Panel, consisting of urologists, oncologists, and cardio-oncologists from India with guidance from an international expert, developed practical, India-specific recommendations using a modified Delphi methodology. Evidence on the cardiovascular effects of ADT and ARPIs was reviewed and contextualized for Indian clinical practice. Consensus was defined as \u226575% agreement among panelists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The panel recommended comprehensive baseline lifestyle and cardiometabolic assessment, use of simplified cardiovascular risk checklists, baseline ECG and metabolic profiling, and risk stratification into low, intermediate, or high cardiovascular risk. GnRH antagonists were preferred for high-risk patients, with referral to cardiologists for those at intermediate or high risk. Ongoing cardiometabolic monitoring, lifestyle interventions, and integration of the ABCDE (A \u2013 Awareness and Aspirin: Identify risk factors and consider prophylactic aspirin if appropriate, B \u2013 Blood Pressure: Monitor and manage hypertension, C \u2013 Cholesterol\/Cigarettes: Manage cholesterol and avoid smoking, D \u2013 Diet\/Diabetes: Promote a heart-healthy diet and control blood sugar, E \u2013 Exercise: Encourage regular physical activity). Cardio-Oncology framework were emphasized. A multidisciplinary care model involving oncologists, urologists, cardiologists, and primary care providers was strongly recommended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>With increasing use of ADT and ARPIs and the high burden of cardiovascular comorbidities in Indian men with PCa, proactive cardiovascular risk assessment, individualized treatment selection, and coordinated multidisciplinary management are essential. This expert consensus provides actionable, India-specific guidance to balance oncologic efficacy with cardiovascular safety and improve long-term outcomes and quality of life for patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1787811","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:36:47Z","timestamp":1784194607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Indian Delphi consensus on cardiovascular risk mitigation in prostate cancer management"],"prefix":"10.3389","volume":"16","author":[{"given":"Ganesh","family":"Bakshi","sequence":"first","affiliation":[{"name":"Uro-oncology, P D Hinduja Hospital and Medical Research Center","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lyon","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Joshi","sequence":"additional","affiliation":[{"name":"Dept. Of Medical Oncology, Dept. Of Medical Oncology, Tata Memorial Hospital","place":["Navi Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Agarwala","sequence":"additional","affiliation":[{"name":"Medical Oncology & Hemat Oncology, & Consultant Cardio Oncologist, Narayana Health, Howrah\/Kolkata","place":["West Bengal, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Raghunath","sequence":"additional","affiliation":[{"name":"HCG Bangalore Institute of Oncology","place":["Bangalore, Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjai Kumar","family":"Addla","sequence":"additional","affiliation":[{"name":"Apollo Cancer Institute","place":["Hyderabad, Telangana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Taneja","sequence":"additional","affiliation":[{"name":"Andrology and Robotic Surgery, Indraprastha Apollo Hospitals","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Mandani","sequence":"additional","affiliation":[{"name":"Urology and Kidney Transplant, Medanta The Medicity","place":["Gurugram, Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhalchandra","family":"Kashyapi","sequence":"additional","affiliation":[{"name":"Deenanath Mangeshkar Hospital","place":["Pune, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Mazumdar Shaw Medical Centre","place":["Bangalore, Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sharma","sequence":"additional","affiliation":[{"name":"Basavatarakam Indo-American Cancer Hospital","place":["Hyderabad, Telangana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Fortis Memorial Research Institute (FMRI)","place":["Gurugram, Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Nagar","sequence":"additional","affiliation":[{"name":"Kokilaben Dhirubhai Ambani Hospital","place":["Indore, Madhya Pradesh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Srivathsan","sequence":"additional","affiliation":[{"name":"Apollo Hospitals","place":["Chennai, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keval","family":"Patel","sequence":"additional","affiliation":[{"name":"Aayushyam Speciality Hospital","place":["Ahmedabad, Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Patel","sequence":"additional","affiliation":[{"name":"Zydus Cancer Hospital","place":["Ahmedabad, Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetan","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sheth Gordhandas Sunderdas (GS) Medical College and King Edward Memorial (KEM) Hospital","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Lai","sequence":"additional","affiliation":[{"name":"Ferring Pharmaceuticals","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurba","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Japan, Australia, Korea (JAK), Southeast Asia (SEA) & India, Medical Operations","place":["Ferring Pharmaceuticals, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhanshu","family":"Pandey","sequence":"additional","affiliation":[{"name":"Ferring Pharmaceuticals","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashishsingh","family":"Rajput","sequence":"additional","affiliation":[{"name":"Ferring Pharmaceuticals","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B2","unstructured":"Cancer Over Time\n          \n          2025"},{"key":"B3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/iju.iju_27_24","article-title":"Descriptive\u00a0epidemiology of prostate cancer in India, 2012\u20132019: Insights from the National Cancer Registry Programme","volume":"40","author":"Sankarapillai","year":"2024","journal-title":"Indian J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2022\/57485.17161","article-title":"Clinicopathological profile of prostate cancer patients: A 10 years retrospective study from a tertiary care centre, North East India","volume":"16","author":"Sailo","year":"2022","journal-title":"J\u00a0Clin Diagn Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.555475","article-title":"Cardiovascular complications of prostate\u00a0cancer treatment","volume":"11","author":"Wilk","year":"2020","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51279","article-title":"Risk factors for cardiovascular-specific mortality in patients with prostate cancer: A surveillance, epidemiology, and end results (SEER)-based study","volume":"15","author":"Alhadeethi","year":"2023","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30407-8","article-title":"The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990\u20132016","volume":"6","author":"Prabhakaran","year":"2018","journal-title":"Lancet Glob Health"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.914875","article-title":"Causes of death among prostate cancer patients aged 40 years and older in the United States","volume":"12","author":"Ye","year":"2022","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100606","article-title":"Current status and future perspective on the management of metastatic castration-sensitive prostate cancer","volume":"32","author":"Blas","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/RRU.S303215","article-title":"Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: An update for practicing urologists, clinicians and medical providers","volume":"14","author":"Choi","year":"2022","journal-title":"Res Rep Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: The primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2024.07.004","article-title":"Cardiovascular risks of Asian patients on androgen-receptor-targeted agents for prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Kyaw","year":"2024","journal-title":"Prostate Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41391-024-00792-5","article-title":"Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis","volume":"27","author":"Ong","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/and.13119","article-title":"Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer","volume":"50","author":"Shiota","year":"2018","journal-title":"Andrologia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.47836\/mjmhs.18.6.34","article-title":"Predictors of coronary heart disease (CHD) among Malaysian adults: Findings from MyDiet-CHD study","volume":"18","author":"Wan Musa","year":"2022","journal-title":"Malays J Med Health Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.06.006","article-title":"Body composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study","volume":"68","author":"Van Londen","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.09.012","article-title":"Cardiovascular risk in prostate cancer","volume":"6","author":"Leong","year":"2024","journal-title":"JACC CardioOncology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2024-0057","article-title":"Adiponcosis interplay: adipose tissue, microenvironment and prostate cancer","volume":"35","author":"Zazzo","year":"2024","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.euros.2022.11.002","article-title":"HbA1c variability and cardiovascular events in patients with prostate cancer receiving androgen deprivation therapy","volume":"47","author":"Chan","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2013.11.004","article-title":"Molecularly targeted cancer therapy: some lessons from the past decade","volume":"35","author":"Huang","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00345-024-04852-2","article-title":"Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network","volume":"42","author":"Merseburger","year":"2024","journal-title":"World J Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bea.2023.100089","article-title":"Analysis of various techniques for ECG signal in healthcare, past, present, and future","volume":"6","author":"Anbalagan","year":"2023","journal-title":"BioMed Eng Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.aprim.2025.103284","article-title":"Electrocardiographic evaluation in healthy Mexican students","volume":"57","author":"Dervil Arroyo","year":"2025","journal-title":"Aten Primaria"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1386597","article-title":"Cardio-oncology in advanced prostate cancer","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1345322","article-title":"Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology","volume":"14","author":"Poon","year":"2024","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12472","article-title":"Androgen deprivation therapy is associated with diabetes: Evidence from meta\u2010analysis","volume":"7","author":"Wang","year":"2016","journal-title":"J Diabetes Investig"},{"key":"B28","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1186\/s12872-024-04421-w","article-title":"Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis","volume":"24","author":"Khorram","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-025-02239-2","article-title":"Effect of androgen deprivation therapy on cardiovascular function in patients with advanced prostate carcinoma: a prospective cohort study","volume":"16","author":"Arulraj","year":"2025","journal-title":"Indian J Surg Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.04.080","article-title":"Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study","volume":"317","author":"Youn","year":"2020","journal-title":"Int J Cardiol"},{"key":"B31","article-title":"Evaluation of prostate cancer characteristics in four populations worldwide","volume":"15","author":"Zeigler-Johnson","year":"2008","journal-title":"Can J Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164157","article-title":"Cardiologist-performed baseline evaluation with an assessment of coronary status for prostate cancer patients undergoing androgen deprivation therapy: Impact on newly diagnosed coronary artery disease","volume":"15","author":"Rog\u00e9","year":"2023","journal-title":"Cancers"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03433-3","article-title":"Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice","volume":"39","author":"Davey","year":"2021","journal-title":"World J Urol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00555-0","article-title":"Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan","volume":"26","author":"Shao","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.09.004","article-title":"Comparative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists among patients diagnosed with prostate cancer: A systematic review and meta-analysis of real-world evidence studies","volume":"8","author":"Patel","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1157857","article-title":"Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis","volume":"14","author":"Gu","year":"2023","journal-title":"Front Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1523794","article-title":"Comparing the risk of cardiovascular disease between degarelix and gonadotropin-releasing hormone agonists: a systematic review and meta-analysis","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2024.06.006","article-title":"Cardiovascular considerations after cancer therapy","volume":"7","author":"Blaes","year":"2025","journal-title":"JACC CardioOncology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.7355","article-title":"Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies","volume":"15","author":"Kokorovic","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0200-z","article-title":"Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer","volume":"23","author":"Newton","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0000000000003095","article-title":"Resistance exercise training increases muscle mass and strength in prostate cancer patients on androgen deprivation therapy","volume":"55","author":"Houben","year":"2023","journal-title":"Med Sci Sports Exerc"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.09.012","article-title":"Immediate versus delayed exercise on health-related quality of life in patients initiating androgen deprivation therapy: Results from a year-long randomised trial","volume":"8","author":"Taaffe","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B45","unstructured":"FEEL+ Program"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0028","article-title":"Survivorship, Version 1.2021: Featured updates to the NCCN guidelines","volume":"19","author":"Tevaarwerk","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.012521","article-title":"ABCDE steps for heart and vascular wellness following a prostate cancer diagnosis","volume":"132","author":"Guan","year":"2015","journal-title":"Circulation"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.6515\/ACS.202505_41(3).20250224A","article-title":"Taiwan consensus for the management of cardiovascular risks and complications in patients with prostate cancer","volume":"41","author":"Wei-Ting Chang","year":"2025","journal-title":"Acta Cardiol Sin"},{"key":"B49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40959-025-00322-9","article-title":"Principles of optimal multidisciplinary management of prostate cancer in clinical practice","volume":"11","author":"Cirne","year":"2025","journal-title":"Cardio-Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-023-01909-3","article-title":"Approaches to prevent and manage cardiovascular disease in patients receiving therapy for prostate cancer","volume":"25","author":"Ng","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01215-x","article-title":"Use of electrocardiogram monitoring in adult patients taking high-risk QT interval prolonging medicines in clinical practice: Systematic review and meta-analysis","volume":"45","author":"Putnikovic","year":"2022","journal-title":"Drug Saf"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0547-7","article-title":"Effect of degarelix, a gonadotropin-releasing hormone receptor antagonist for the treatment of prostate cancer, on cardiac repolarisation in a randomised, placebo and active comparator controlled thorough QT\/QTc trial in healthy men","volume":"37","author":"Olsson","year":"2017","journal-title":"Clin Drug Investig"},{"key":"B53","unstructured":"Drug-Drug Interactions and QT Prolongation as a Commonly Assessed Cardiac Effect - Comprehensive Overview of Clinical Trials | BMC Pharmacology and Toxicology | Full Text"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106094","article-title":"Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis","volume":"177","author":"Cui","year":"2022","journal-title":"Pharmacol Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101688","article-title":"The effect of SGLT2 inhibition on prostate cancer: Mendelian randomization and observational analysis using electronic healthcare and cohort data","volume":"5","author":"Zheng","year":"2024","journal-title":"Cell Rep Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.xfre.2022.11.011","article-title":"Clinical development of the GnRH agonist leuprolide acetate depot","volume":"4","author":"Chwalisz","year":"2022","journal-title":"FS Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/srep26220","article-title":"Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE-\/- mice","volume":"6","author":"Knutsson","year":"2016","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2025.07.001","article-title":"An\u00a0Indian\u00a0expert consensus on patient-profile-based implementation of guideline-directed\u00a0medical therapy in the management of heart failure with reduced ejection fraction: APPROACH-HF","volume":"31","author":"Ponde","year":"2025","journal-title":"J Card Fail"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1161\/circ.146.suppl_1.12295","article-title":"Abstract 12295: Relation between withdrawal of heart failure therapy and left ventricular function after improvement of cancer therapeutics related cardiac dysfunction","volume":"146","author":"Lee","year":"2022","journal-title":"Circulation"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1787811\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:36:50Z","timestamp":1784194610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1787811\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":59,"alternative-id":["10.3389\/fonc.2026.1787811"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1787811","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1787811"}}